Cerevel Therapeutics is dedicated to addressing neuroscience diseases by unraveling the complexities of the brain. Utilizing a differentiated approach that integrates expertise in neurocircuitry and receptor selectivity, Cerevel develops a diverse portfolio of pre-commercial assets targeting a range of central nervous system disorders, such as schizophrenia, epilepsy, Parkinson’s disease, and substance use disorder. Headquartered in the Greater Boston area, Cerevel fosters a culture built on trust, respect, courage, curiosity, and compassion, with a strong emphasis on patient-centricity. The organization is committed to pushing the boundaries of scientific knowledge and delivering impactful therapies that improve patients' lives, while encouraging a workplace environment that values collaboration, diverse perspectives, and innovative thinking.